Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial

Simple item page
dc.contributor.authorDorhout Mees, Sanne M
dc.contributor.authorAlgra, Ale
dc.contributor.authorVandertop, William Peter
dc.contributor.authorvan Kooten, Fop
dc.contributor.authorKuijsten, Hans A J M
dc.contributor.authorBoiten, Jelis
dc.contributor.authorvan Oostenbrugge, Robert
dc.contributor.authorAl-Shahi Salman, Rustam
dc.contributor.authorLavados, Pablo
dc.contributor.authorRinkel, Gabriel J E
dc.contributor.authorvan den Bergh, Walter M
dc.date.accessioned2017-05-25T16:27:24Z
dc.date.available2017-05-25T16:27:24Z
dc.date.issued2012
dc.description.abstractBackground Magnesium sulphate is a neuroprotective agent that might improve outcome after aneurysmal subarachnoid haemorrhage by reducing the occurrence or improving the outcome of delayed cerebral ischaemia. We did a trial to test whether magnesium therapy improves outcome after aneurysmal subarachnoid haemorrhage. Methods We did this phase 3 randomised, placebo-controlled trial in eight centres in Europe and South America. We randomly assigned (with computer-generated random numbers, with permuted blocks of four, stratified by centre) patients aged 18 years or older with an aneurysmal pattern of subarachnoid haemorrhage on brain imaging who were admitted to hospital within 4 days of haemorrhage, to receive intravenous magnesium sulphate, 64 mmol/day, or placebo. We excluded patients with renal failure or bodyweight lower than 50 kg. Patients, treating physicians, and investigators assessing outcomes and analysing data were masked to the allocation. The primary outcome was poor outcome—defined as a score of 4–5 on the modified Rankin Scale—3 months after subarachnoid haemorrhage, or death. We analysed results by intention to treat. We also updated a previous meta-analysis of trials of magnesium treatment for aneurysmal subarachnoid haemorrhage. This study is registered with controlled-trials.com (ISRCTN 68742385) and the EU Clinical Trials Register (EudraCT 2006-003523-36). Findings 1204 patients were enrolled, one of whom had his treatment allocation lost. 606 patients were assigned to the magnesium group (two lost to follow-up), 597 to the placebo (one lost to follow-up). 158 patients (26·2%) had poor outcome in the magnesium group compared with 151 (25·3%) in the placebo group (risk ratio [RR] 1·03, 95% CI 0·85–1·25). Our updated meta-analysis of seven randomised trials involving 2047 patients shows that magnesium is not superior to placebo for reduction of poor outcome after aneurysmal subarachnoid haemorrhage (RR 0·96, 95% CI 0·84–1·10). Interpretation Intravenous magnesium sulphate does not improve clinical outcome after aneurysmal subarachnoid haemorrhage, therefore routine administration of magnesium cannot be recommended. Funding Netherlands Heart Foundation, UK Medical Research Council.
dc.format.extent6
dc.identifier.citationThe Lancet, May 2012, 380(9836):44-9
dc.identifier.urihttp://hdl.handle.net/11447/1336
dc.identifier.urihttp://dx.doi.org/10.1016/S0140-6736(12)60724-7
dc.language.isoen_US
dc.publisherElsevier
dc.subjectMagnesium sulphate
dc.subjectaneurysmal subarachnoid haemorrhage
dc.subjectrandomised/placebo-controlled trial
dc.titleMagnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial
dc.typeArtículo

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2) a randomised placebo-controlled trial.pdf
Size:
317.53 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services